Video

Noninvasive biomarker tests diagnose urothelial cancer in patients with hematuria

“What was very impressive from the study was by sequentially using Cxbladder Triage, Detect, and Resolve, we could not only segregate those who had cancer versus not, but also those who had low-risk tumors versus high-risk tumors,” says Jay Raman, MD, FACS.

In this video, Jay Raman, MD, FACS,discusses the findings and takeaways of the study, “The diagnostic performance of Cxbladder Resolve, alone and in combination with other Cxbladder tests, in the identification and priority evaluation of patients at risk for urothelial carcinoma,” published in the Journal of Urology. Raman is a professor and chair of urology at Penn State Health Milton S. Hershey Medical Center, Penn State University, Pennsylvania.

Related Videos
Marah C. Hehemann, MD, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Diverse group of doctors | © Flamingo Images - stock.adobe.com
Man talking with a doctor | Image Credit: © RFBSIP - stock.adobe.com
Evan Panken, MD, answers a question during a video interview
Illustration of Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
Amy Pearlman, MD, answers a question during a video interview
Team of surgeons | Image Credit: © shefkate - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.